1628604-87-4

Basic information

• Product Name: ((3-bromophenyl)imino)dimethyl-λ⁶-sulfanone
• CAS NO: 1628604-87-4
• Molecular Weight: 248.143
• Mol File: 1628604-87-4.mol

Chemical Properties

• Boiling Point: 334.5±44.0 °C(Predicted)
• Density: 1.44±0.1 g/cm3(Predicted)
• CAS DataBase Reference: ((3-bromophenyl)imino)dimethyl-λ⁶-sulfanone(CAS DataBase Reference)
• NIST Chemistry Reference: ((3-bromophenyl)imino)dimethyl-λ⁶-sulfanone(1628604-87-4)
• EPA Substance Registry System: ((3-bromophenyl)imino)dimethyl-λ⁶-sulfanone(1628604-87-4)

Safety Data

• Hazardous Substances Data: 1628604-87-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
((3-bromophenyl)imino)dimethyl-λ⁶-sulfanone is used as a key intermediate in organic synthesis for the creation of a variety of complex organic molecules. Its unique structure allows for multiple points of reactivity, facilitating the formation of diverse chemical products.
Used in Pharmaceutical Research:
In the pharmaceutical industry, ((3-bromophenyl)imino)dimethyl-λ⁶-sulfanone serves as a valuable precursor in the development of new drugs. Its potential involvement in the synthesis of active pharmaceutical ingredients makes it an important component in medicinal chemistry.
Used in Agrochemical Production:
((3-bromophenyl)imino)dimethyl-λ⁶-sulfanone also finds application in the production of agrochemicals, where it may contribute to the synthesis of pesticides, herbicides, or other agricultural chemicals. Its role in these processes can lead to the development of more effective and targeted products for crop protection.

Upstream product

• 1520-31-6 dimethylsulfoximine 
• 591-18-4 1-Bromo-3-iodobenzene 

Relevant articles and documents

INDAZOLE COMPOUNDS

Disclosed herein are indazole compounds and methods of treating diseases and/or conditions (e.g., cancer) with the indazole compounds disclosed herein.

AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING EFFECT

Disclosed is a compound which is useful as an AMPK activator. A compound represented by formula: or its pharmaceutically acceptable salt, wherein X is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, or substituted or unsubstituted heterocyclyl; R1 is hydrogen, halogen, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted acyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, or substituted or unsubstituted alkyloxycarbonyl; R2 is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, or the like; R3 is halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, or the like; and R4 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or the like.

NEW AZABENZIMIDAZOLE DERIVATIVES

The present invention relates to compounds of general formula I, wherein the group R1, R2, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW AZABENZIMIDAZOLE DERIVATIVES

The present invention relates to compounds of general formula (I), wherein the group R1, R2, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides of formula (1) and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid(benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.